Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 12-Month Open Label Follow-Up Period

NCT02244541 is registered in ClinicalTrials.gov with Anavex Life Sciences Corp. as lead sponsor.

NCT NCT02244541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02244541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 12-Month Open Label Follow-Up Period
Lead sponsor
Anavex Life Sciences Corp.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2014
Completion date
November 30, 2016
Enrollment
32 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease